Pacira BioSciences Inc. Investors: Important Actions to Take
Investors in Pacira BioSciences Inc. are urged to be proactive amid recent developments that may impact their financial standing. The Portnoy Law Firm is available to assist those impacted, offering consultations at no charge. This allows affected investors a chance to understand their options for recovering losses due to recent events surrounding the company.
Key Details for Pacira Investors
Recently, a class action lawsuit has been initiated for investors who purchased Pacira securities during a significant time frame. This class period began on August 2, 2023, and concluded on August 8, 2024. Investors should act quickly as they have until March 14, 2025, to file a lead plaintiff motion.
Understanding the Legal Landscape
For those who wish to explore their legal rights further, the Portnoy Law Firm invites you to reach out to attorney Lesley F. Portnoy. She is available via phone at 310-692-8883 or you can send an email to lesley@portnoylaw.com. Addressing potential legal concerns is crucial for reclaiming any losses suffered.
Recent Patent Infringement Case Impact
An essential turn of events occurred on August 9, 2024, when Pacira announced a legal defeat in a patent infringement dispute with eVenus. The company revealed the court's decision to invalidate U.S. Patent No. 11,033,495, which protected their flagship product, Exparel. This patent is vital, as Exparel accounts for approximately 80% of the company’s total revenue.
Concerns Arising from the Lawsuit Outcome
The invalidation of the ‘495 patent presents a substantial risk. Analysts have raised alarms that it may weaken the foundation for Pacira’s remaining patents. Such a situation could lead to increased competition from generic alternatives, which would likely pressure the company’s revenue and escalate litigation expenses.
Market Reaction to Recent Developments
The market reacted sharply following the announcement of the lawsuit outcome. Pacira's stock, which closed at $22.36 per share on August 8, 2024, suffered a dramatic decline, dropping to $11.70 per share the following day. This drastic fall of over 47% has understandably caused alarm among investors.
Your Next Steps
In light of these unfolding events, it's essential for investors to stay informed. The Portnoy Law Firm remains dedicated to representing those affected by corporate missteps. Their experience, with over $5.5 billion recovered for investors, highlights their commitment to serving those who have faced unfair losses.
Resources for Investors
To learn more about your options and review additional information, please visit the Portnoy Law Firm website. They facilitate the submission of transaction details and provide complimentary case evaluations to potential clients wishing to pursue claims. This proactive step can help mitigate losses and clarify your legal standing.
Frequently Asked Questions
What is the class action lawsuit against Pacira BioSciences about?
The lawsuit pertains to investors who purchased securities between August 2, 2023, and August 8, 2024. They may have compensation options due to recent legal developments affecting the company.
What did the recent court ruling involve?
The court ruled against Pacira, invalidating a crucial patent that protects their primary product, Exparel, raising concerns about future revenue and competition.
How can I contact the Portnoy Law Firm?
You can contact attorney Lesley F. Portnoy at 310-692-8883 or via email at lesley@portnoylaw.com for a consultation on your legal rights.
When is the deadline to join the class action lawsuit?
The deadline to file a lead plaintiff motion for the class action is March 14, 2025.
What percentage of company revenue does Exparel account for?
Exparel accounts for approximately 80% of Pacira's total revenue, making the recent patent ruling particularly impactful.
